Cannabis Testing Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cannabis testing services market size was valued at USD 359.68 million in 2025 and is estimated to grow from USD 397.85 million in 2026 to reach USD 688.46 million by 2031, at a CAGR of 11.59% during the forecast period (2026-2031). This report is Segmented by Service (Potency Testing, Terpene Profiling, Heavy Metal Testing, Pesticide Screening, Microscopy Testing, Residual Solvent Screening, and More), End Use (Independent Testing Laboratories, Pharmaceutical & Research Institutes, Other End Users), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Cannabis Testing Services Market Trends and Insights

Rising Cannabis Legalization Across Medical and Recreational Channels

Each new licensing system creates immediate demand in the cannabis testing services market because no commercial batch can move without a Certificate of Analysis. Germany’s Cannabis Act, which took effect in April 2024, required testing for pesticides, mycotoxins, heavy metals, and microorganisms for cannabis social club products, which widened the service need within a major European economy. Japan’s amended Cannabis Control Act, enforced from December 2024, created a new mandatory testing requirement for residual narcotic components in CBD-containing products and raised the need for advanced LC-MS/MS capability. The practical effect is larger than a simple increase in legal sales because each regulated product lot usually triggers several tests rather than one. The cannabis testing services market, therefore, grows faster than end-product volume when legalization expands through both medical and adult-use channels. Early-stage jurisdictions also tend to begin with limited accredited lab capacity, which raises utilization quickly once commercial production starts in the cannabis testing services market.

Expansion of Pharmaceutical-Grade Cannabis Production

The cannabis testing services market is also benefiting from the shift of cannabis from an agricultural product to a pharmaceutical dosage form. In Brazil, ANVISA-linked pharmaceutical quality requirements for CBD oral solutions increased the need for outsourced chromatographic and microbiological assays at accredited contract laboratories. This raises the testing burden because clinical and therapeutic products need more than basic potency confirmation. The U.S. Pharmacopeia’s republication of draft chapter USP < 1568> in 2025 pointed toward more formal requirements for stability, extractables, leachables, and dose uniformity in cannabis clinical research. Those expectations push laboratories toward validated methods, tighter documentation, and broader scientific capability. As pharmaceutical development pipelines deepen, the cannabis testing services market should keep shifting part of its revenue mix toward higher-value submissions rather than simple routine compliance work.

Fragmented State, Federal, and Cross-Border Rules

The cannabis testing services market still faces a heavy coordination burden because rules differ across states, countries, and product categories. In the United States, a laboratory that is licensed and accredited in one state cannot automatically process samples for another state because test panels, action limits, and chain-of-custody rules vary in meaningful ways. The USDA requirement for hemp laboratories to register with the DEA by December 31, 2025 added another compliance layer that does not always align cleanly with state systems. These differences raise documentation costs and make multi-state expansion slower for smaller operators in the cannabis testing services market. They also increase the risk that a facility is built around a rule set that later changes before utilization reaches target levels. The result is slower scaling, more cautious capital deployment, and continued dependence on jurisdiction-specific operating models in the cannabis testing services market.

Other drivers and restraints analyzed in the detailed report include:

• Higher Product Recall Risk From Contaminant Non-Compliance
• Adoption of AI-Enabled LIMS for ISO 17025 Workflows
• High Capital Cost for Advanced Analytical Instrumentation

Segment Analysis

Potency testing held 68.13% of the cannabis testing services market share in 2025, which made it the largest service segment by a wide margin. Its position reflects the fact that cannabinoid labeling is mandatory for licensed products across flower, concentrates, edibles, topicals, and inhalables. The segment also benefits from repeat volume because each commercial batch still needs documented potency confirmation before release. Ohio’s April 2025 reporting update, which moved laboratories away from dry-weight reporting and toward as-is moisture-corrected values, showed that potency testing methods are still being refined even in established state systems. That keeps the service active across mature and newly regulated markets and gives it a foundation role in the cannabis testing services market.

Terpene Profiling is projected to grow at a 13.28% CAGR through 2031, which makes it the fastest-expanding service line in the cannabis testing services market. A 2024 study in Analytical and Bioanalytical Chemistry showed simultaneous LC-APCI-MS/MS quantification of 16 terpenes and 7 cannabinoids, which supported more complete chemovar characterization and reduced run times versus older approaches. That matters because manufacturers are using terpene data for differentiation and because clinical and consumer expectations are moving beyond simple THC and CBD disclosure. Pesticide Screening, Heavy Metal Testing, and Residual Solvent Screening are also expanding as analyte lists grow in mature regulatory systems. Mycotoxin Testing is gaining more weight after contamination events exposed the limits of legacy microbial methods. Microscopy Testing and other cannabis testing services remain smaller but continue to serve forensic, research, and product verification needs within the cannabis testing services industry.

Complete Report Scope:

• By Service
  • Potency Testing
  • Terpene Profiling
  • Heavy Metal Testing
  • Pesticide Screening
  • Microscopy Testing
  • Residual Solvent Screening
  • Mycotoxin Testing
  • Other Cannabis Testing Services
• By End Use
  • Independent Testing Laboratories
  • Pharmaceutical & Research Institutes
  • Other End Users (Cannabis Dispensaries, Cannabis Cultivators and Growers, etc.)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 53.63% of the cannabis testing services market size in 2025, which made it the largest regional contributor. The United States remained the core revenue base because state licensing systems continued to require independent laboratory testing across commercial product formats. Canada’s March 2025 amendments raised micro-class production ceilings while keeping full analytical testing obligations in place, which showed that a mature national framework can simplify administration without lowering the testing bar. ISO/IEC 17025 expectations and the USDA hemp laboratory registration framework continue to raise operating thresholds, which support premium positioning for qualified operators in the cannabis testing services market.

Europe is moving into a more structured phase of the cannabis testing services market, even though it remains less scaled than North America. Germany’s Cannabis Act created immediate testing demand for pesticides, mycotoxins, heavy metals, and microbial contaminants in social club production, which gave accredited laboratories a clearer commercial role. This regulatory shift matters because Germany is one of the region’s largest economies and often sets a practical benchmark for surrounding markets. The United Kingdom, France, Italy, and Spain are still moving at different speeds, but the direction of travel remains toward tighter product control and more formal laboratory requirements in the cannabis testing services market.

Asia-Pacific is projected to expand at a 14.06% CAGR through 2031, which makes it the fastest-growing regional block in the cannabis testing services market. Japan is the main driver because the amended Cannabis Control Act now requires residual narcotic component testing for CBD-containing products and enforces THC limits below many international reference points. PJLA Japan reported stronger inquiry levels from testing institutions after the 2025 legal amendment, which points to a real buildout of accredited capacity rather than only policy interest. Australia also supports demand through the TGO 93 framework for medicinal cannabis testing. South Korea, China, and India remain early in formation, while South America and the Middle East and Africa offer longer-term opportunities as domestic lab capability and pharmaceutical-grade requirements continue to develop in the cannabis testing services market.

List of Companies Covered in this Report:

• Adact Medical Ltd.
• Agilent Technologies
• AZ Biopharm GmbH
• BRITISH CANNABIS
• CW Analytical
• Eurofins
• GreenLeaf Lab
• Kaycha Labs
• Laboratorium Dr. Liebich
• PerkinElmer
• PharmLabs LLC
• PhytoVista Laboratories
• Praxis Laboratory
• ProVerde Laboratories
• Saskatchewan Research Council
• SC Labs
• SGS Société Générale de Surveillance SA
• Shimadzu
• Steep Hill, Inc.
• Thermo Fisher Scientific
• Waters Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support